Letter from the Chief Executive NICE,
to the Chairman of the Committee (NC 62A)
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE;
At the Committee hearing on 30 January, Sir
Michael Rawlins indicated that the Institute would be submitting
further evidence in response to written submissions from other
witnesses and statements made by witnesses at earlier hearings.
We wrote to you last week, setting out our response
to the suggestion, by the deputy Editor of the Drugs and Therapeutics
Bulletin, that we had failed to respond to correspondence from
the Bulletin about their observations on the Institute's revised
guidance on zanamivir.
Two papers are attached to this letter. The
first deals with the criticisms of the Institute's guidance made
by the Drugs and Therapeutics Bulletin, the British National Formulary
and others. The second responds to factual inaccuracies and misunderstanding
of the Institute's processes and methodologies, which the Committee
may find helpful.
Please let me know if you require any further
5 February 2002